Top Banner
Overview of Current Synthetics Darrell L. Davis Laboratory Director DEA South Central Laboratory Dallas, Texas O OH H H N O
35

Overview of Current Synthetics

Jan 01, 2016

Download

Documents

shelly-golden

Overview of Current Synthetics. Darrell L. Davis Laboratory Director DEA South Central Laboratory Dallas, Texas. Objectives. Discuss: Spice/K2/Cannabinoid/Bath Salts Discuss DEA Scheduling Procedures. SPICE/K2/CANNABINOIDS. Unregulated mixture of dried herbs - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Overview of Current Synthetics

Overview of Current Synthetics

Darrell L. DavisLaboratory Director

DEA South Central LaboratoryDallas, Texas

O

O HH

HN

O

Page 2: Overview of Current Synthetics

Objectives

• Discuss: Spice/K2/Cannabinoid/Bath Salts

• Discuss DEA Scheduling Procedures

Page 3: Overview of Current Synthetics

SPICE/K2/CANNABINOIDS

Page 4: Overview of Current Synthetics

SPICE

• Unregulated mixture of dried herbs– Ingredients are commonly listed as “Indian

Warrior” and “Wild Dagga” or “Lion’s Tail”• “Each of which are potentially bioactive herbs”

– No mention of additives or other compounds that have a pharmacological activity

Page 5: Overview of Current Synthetics
Page 6: Overview of Current Synthetics

What are they?

Page 7: Overview of Current Synthetics

Spice Facts – Street NamesSpiceSpice GoldKushLegal EagleEarth ImpactScopeSpice EgyptK2SenceYucatan FireSmoke

GorillazSkunkGenieGalaxyGoldSpace TruckinSolar FlareMoon RocksBlue LotusAromaChillXHighdi’sAlmdrohner

Page 8: Overview of Current Synthetics

Spice Facts

Street names:K2Fake WeedSpiceSpice Gold

Yucatan GoldSkunkGenieVoodoo

Effects:hallucinationssevere agitationelevated heart rateelevated blood pressurered eyesmood alteration

www.sciencedaily.com

Page 9: Overview of Current Synthetics

A Little Background

• Synthetic cannabinoids were created in an attempt to manufacture a legitimate pharmaceutical that would produce the pain relieving effects of marijuana without producing the “high.”

• Compounds are named for whom or where they were synthesized.– JWH-018 – John W. Huffman– HU-210 – Hebrew University

Page 10: Overview of Current Synthetics

History

• 2004 – “Spice” brand products sold on the internet and Head shops.

• 2007-2008 – Spice monitoring begins• Dec 2008 – Two German labs identify JWH-

018 in Spice products• Austria & Switzerland ban herbal incense• Jan 2009 – Two German labs and the National

Institute of Health Sciences in Japan identify CP 47,497 in seven “Spice” products

Page 11: Overview of Current Synthetics

History

• Jan 2009 – Germany banned CP 47,497 and JWH-018

• Jan 2009 – U.S. Customs and Border Patrol report a “small but verifiable” amount of HU-210

• Feb 2009 – France banned CP 47,497, JWH-018, and HU-210

Page 12: Overview of Current Synthetics

History

• Apr 2009 – K2 hits the market• Aug 2009 – UK Advisory Council on the Misuse

of Drugs advised the government to control some synthetic cannabinoids.

• Sept 2009 – K2 was reported in schools in the Kansas area.

• Feb 2010 – The single source of K2 in Lawrence, KS was raided

Page 13: Overview of Current Synthetics

• Since then the use of synthetic cannabinoids has spread like wild fire

• Several states have enacted emergency legislation making it illegal

• The Federal Government has emergency scheduled JWH-018, JWH-073, JWH-250, & CP 47,497 (C8 also) as of March 1, 2011.

• HU-210 is already covered under the Federal Analogue Act

History

Page 14: Overview of Current Synthetics

How do these drugs work?• They work just like marijuana!• They bind to chemical receptors (CB1) in the central

nervous system designed to bind with natural endocannabinoinds manufactured by your body.– Endocannabinoids are responsible for physiological

processes• Appetite• Mood• Memory• Pain Sensation

• These drugs are habit forming and slightly addictive.

Page 15: Overview of Current Synthetics

How much does it cost?

Page 16: Overview of Current Synthetics

How is it used?

Page 17: Overview of Current Synthetics

What now?

• Making synthetic cannabinoids illegal is problematic– How do we test it?– Which compounds do we make illegal?

• Will the Controlled Substances Analog Act cover isomers?

– Where do we get known chemical standards to compare street drugs to?

– How do we testify to something that has yet to be researched?

Page 18: Overview of Current Synthetics

Resources

• www.drugfree.org Forendex (SAFS)

• www.theantidrug.com CLIC_List• www.dare.com SWAFS_List• www.fairbankscd.org• www.wikipedia.org• www.jwh-info.com• www.erowid.org • www.deadiversion.usdoj.gov/drugs_concern/

spice/index.html

Page 19: Overview of Current Synthetics

Bath Salts, What are they?

Spice: A never ending story?

• 3,4-Methylenedioxypyrovalerone (MDPV) is a designer drug of the phenethylamine class. MDPV is structurally related to cathinone, an active alkaloid found in the khat plant, 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine, and other schedule I phenethylamines.

Page 20: Overview of Current Synthetics

Bath Salts, What are they?

Spice: A never ending story?

• MDPV, like some other substances in this class, is a central nervous system (CNS) stimulant. MDPV is also reported to have hallucinogenic effects.

Page 21: Overview of Current Synthetics

Miami 'zombie' attacker may have been using 'bath salts' -- CNN

Spice: A never ending story?

• A naked man who chewed off the face of another man in what is being called a zombie-like attack may have been under the influence of "bath salts," a drug referred to as the new LSD.

Page 22: Overview of Current Synthetics

Types of Scheduling Actions

DEA Office of Diversion Control

• Administrative• Formal

• Legislative• Temporary

Rashad Sims
delete slide
Page 23: Overview of Current Synthetics

Activities

DEA Office of Diversion Control

• Reports of abuse and seizure data prompts DEA to:– Monitor substances through drug seizure and

supply databases– Collect and disseminate scientific information to

law enforcement– Evaluate international trends– Coordinate response with other agencies

Page 24: Overview of Current Synthetics

Formal RulemakingComments / Hearing ?*

* = denotes industry involvement

Petition/ Activity DEA

Initiates

Accepted Rejected

YES

DHHS*

DEAEnforces

DEA ReviewIf accepted YES

NDA* Submission

DHHS Initiates

SchedulingrecommendationDEA Review*

NIDA

FDA*

Advisory* Committee

Domestic Scheduling of Controlled Substances

DHHS*Scientific / Medical Evaluation

DEA Office of Diversion Control

Page 25: Overview of Current Synthetics

Controlled Substance Act

• Under the CSA, there are five schedules under which substances may be classified—Schedule I being the most restrictive. Substances placed onto one of the five schedules are evaluated on:

Page 26: Overview of Current Synthetics

Controlled Substance Act

• actual or relative potential for abuse;• known scientific evidence of pharmacological effects;• current scientific knowledge of the substance;• history and current pattern of abuse;• scope, duration, and significance of abuse;• risk to public health;• psychic or physiological dependence liability; and• whether the substance is an immediate precursor of an already-scheduled substance.

Page 27: Overview of Current Synthetics

Emergency Scheduling

• Before a substance may be placed into emergency scheduling the following factors must be considered:

1)History and Current Pattern of Abuse2)Scope, Duration, and Significance of Abuse3)What, if any, Risk to Public Health

Page 28: Overview of Current Synthetics

Emergency Scheduling

• A substance meeting the statutory requirements for temporary scheduling (21 U.S.C. 811(h)(1)) may only be placed in schedule I. Substances in schedule I are those that have a high potential for abuse, no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision.

Page 29: Overview of Current Synthetics

Emergency Scheduling

DEA Office of Diversion Control

• As of March 2011 and October 2011 The following were placed as Schedule I Controlled Substances

– JWH-018– JWH-073– JWH-200– CP-47,497– CP-47,497 C8 homologue– Mephedrone – MDPV– Methylone

Page 30: Overview of Current Synthetics

Controlled Substance Analogues

DEA Office of Diversion Control

• The issue of whether a substance is a “controlled substance analogue” is an issue of fact which must be determined by a judge or jury. There are three criteria involved in determining whether a substance is a controlled substance analogue.

Page 31: Overview of Current Synthetics

Controlled Substance Analogues

• (1) First, the government must present evidence to support a finding that a substance has a chemical structure substantially similar to a Schedule I or II controlled substance.

Then the government must present evidence that either

Page 32: Overview of Current Synthetics

Controlled Substance Analogues

• (2) the substance has a pharmacological effect substantially similar or greater than a Schedule I or II controlled substance or

• (3) the substance was represented by the seller to have a pharmacological effect substantially similar to or greater than a Schedule I or II controlled substance (example: “this acts just like MDMA”).

Page 33: Overview of Current Synthetics

Current Legislation

• Several bills have been introduced in the to Congress that confront the issue of synthetic drug use and abuse

• There is current legislation being proposed that would add 15 cannabimimetic substances and 11 cathinones, etc., to schedule I (26 substances total) of the CSA.

Page 34: Overview of Current Synthetics